EOM Pharmaceutical Holdings, Inc. (IMUC)
(Delayed Data from OTC)
$0.18 USD
+0.03 (18.71%)
Updated May 3, 2024 10:52 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
EOM Pharmaceutical Holdings, Inc. [IMUC]
Reports for Purchase
Showing records 61 - 80 ( 90 total )
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Key ICT-107 Patent Issued; Looking Towards ICT-107 Interim Analysis
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
1Q13 Results; Phase IIb Interim Recommendation Expected 2Q13
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2012 Results; Looking to ICT-107 Phase IIb Study Interim in 2Q13
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating research coverage due to the termination or loss of the primary and/or secondary analysts responsible for coverage.
Provider: DAWSON JAMES SECURITIES, INC.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
FDA Nod for the ICT-140 IND, Phase IIa Study to Start in 2H13
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage of ImmunoCellular with a Buy rating and $6 price target
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: EOM Pharmaceutical Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G